

	7:30	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	
Nagoya Congress Center	Room 1 (Building 1) 2F Century Hall		8:45~10:45 Symposium 3 New findings elucidated by single cell analysis in gene-modified cell therapy and graft-versus-host disease Noriko Dokki, Kazuaki Yokoyama P.6		11:10~12:00 LS1 CAR-T in multiple myeloma: from clinical trials to the clinic Speaker: Yi Lin Chair: Koichi Akashi (Janssen Pharmaceutical KK)		13:10~15:10 Presidential symposium Gene-modified cell therapies -Present and Future - Yoshiki Akatsuka, Takanori Teshima P.6		15:20~16:50 Pro - Con 1 What should we do for a successful "second" HSCT? Ken-ichi Matsuoka, Akinori Nishikawa P.7		17:00~17:50 AS1 Practical Management of Immune-Related Adverse Events in Hematologic Malignancies Speaker: Takahiro Yamamoto Chair: Kazuhito Yamamoto (AbbVie GK)	18:00~18:30 Business Meeting		
	Room 2 (Building 4) 1F Shiratori Hall (North)		8:45~10:55 Symposium 4 Cell therapy: Industry-University-Government Collaboration Yoshiko Atsuta, Koji Kato P.7		11:10~12:00 LS2 Therapy sequencing strategies with transplants to multiple myeloma Speaker: Junichiro Yuda Chair: Shuji Ozaki (Takeda Pharmaceutical Company Limited)				15:15~16:45 Workshop 2 Post-transplant Cyclophosphamid Haploidentical SCT and Cord Blood Transplantation Naoyuki Uchida, Junichi Sugita P.8		17:00~17:50 AS2 The role of extracorporeal photopheresis (ECP) in the changing treatment landscape in CLL Speaker: Hideyoshi Gremly Chair: Daigo Hashimoto (Mallinckrodt Pharma K.K.)			
	Room 3 (Building 4) 1F Shiratori Hall (South)		8:45~10:45 Symposium 5 Indications for allo-HSCT to acute leukemia from the point of view of pediatrics and internal medicine - seamless HSCT from pediatrics to internal medicine Yasuhiro Okamoto, Ken Ishiyama P.9		11:10~12:00 LS3 Cutting-edge treatment approach for FLT3-mutated AML Speaker: Kenichi Matsuoka Chair: Takanori Teshima (Astellas Pharma Inc.)							17:00~17:50 AS3 The role of immunologic vaccines in the treatment of peripheral T-cell lymphoma Speaker: Shinichi Makita Chair: Kenichi Ishizawa (Takeda Pharmaceutical Company Limited)		
	Room 4 (Building 3) 3F International Conference Room		8:45~10:15 HCTC Workshop Considering work style of HCTC Chairs: Shingo Yano, Yumiko Mizushima Commentator: Tatsuo Ichinohe P.9		11:10~12:00 LS4 Infection management in HSCT - Focus on CMV and fungal infections - Speakers: Yozo Mori, Kazuo Takahashi Chair: Shingo Yano (MSD K.K.)			13:15~14:30 HCTC Recertification Seminar		15:15~16:15 National Survey News		17:00~17:50 AS4 Deepening insight into allogeneic transplantation for myelodysplasia Speaker: Shinsuke Takagi Chair: Keita Kirito (Novartis Pharma K.K.)		
	Room 5 (Building 1) 4F Reception Hall		8:45~10:45 Nursing Symposium Care for patients' families Mitsuko Mori, Yoko Yamamoto P.10		11:10~12:00 LS5 Update on CAR T-cell therapy for Myeloma Speaker: Larry Anderson Chair: Mineo Kurokawa (Bristol-Myers Squibb K.K.)			13:30~14:30 Nursing Group Meeting		15:45~16:45 Team Approach Protection of HSCT donors in coordination process Nami Yamazaki, Kazuo Mori P.10		17:00~17:50 AS5 Treatment strategy for DLBCL - up to date - Speaker: Tatsu Shimoyama Chair: Masayuki Hino (CHUGAI PHARMACEUTICAL CO., LTD.)		
	Room 6 (Building 4) 3F 431+432		8:45~9:45 Oral Session 8 Clinical Outcomes: Malignant Lymphoma I Shigeru Kusumoto P.33	9:50~10:50 Oral Session 9 Clinical Outcomes: Malignant Lymphoma II Shinichi Kako P.34		11:10~12:00 LS6 Cutting edge of HSCT with the advent of CAR-T: The history and future progress Speaker: Kohji Okada Chair: Toshihiro Miyamoto (Kyowa Kirin Co., Ltd.)				15:20~16:35 Oral Session 10 Late Complications II Takuya Yamashita P.35		17:00~17:50 AS6 Treatment Strategy of Acute Myeloid Leukemia (AML) in the Era of Targeted Therapy Speaker: Tetsuo Saitoh, Kenzo Furukawa Chair: Tatsuo Ichinohe (CR Pharmaceuticals Co., Ltd.)		
	Room 7 (Building 2) 2F 222 + 223		8:45~9:45 Oral Session 11 Clinical Outcomes: Others I Masayoshi Masuko P.36	9:50~10:50 Oral Session 12 Clinical Outcomes: Others II Takashi Ikeda P.37		11:10~12:00 LS7 Treatment strategy for myeloid neoplasms: A comparison of hematopoietic cell transplantation and nontransplantative systemic approaches Speakers: Asahiko Harada Chair: Hiromasa Yabe (Clingen K.K.)				15:20~16:35 Oral Session 13 cGVHD Fumihito Tajima P.38		17:00~17:50 AS7 Vaccine strategies after hematopoietic stem cell transplantation Speaker: Keiji Okinaka Chair: Takehiko Mori (GlaxoSmithKline K.K.)		
	Room 8 (Building 2) 2F 224		8:45~9:45 Oral Session 14 VOS, SOS Takayuki Ikezoe P.39	9:50~10:50 Oral Session 15 LTFU, QOL Saiko Kurosawa P.40		11:10~12:00 LS8 Autologous stem cell transplantation for the treatment of CNS lymphoma Speaker: Motomoko Nishikori Chair: Akihiro Tomita (Sumitomo Pharma Co., Ltd.)				15:20~16:35 Oral Session 16 Supportive Care Hirohisa Nakamae P.41		17:00~17:50 AS8 Treatment Strategies for PNH from the Perspective of Bone Marrow Failure Speaker: Masatoshi Sakurai Chair: Akiyuki Takagi-Kondo (Alexion Pharma GK)		
	Room 9 (Building 2) 3F 232 + 233		8:45~9:45 Oral Session 17 Stem Cell Collection II Tokiko Nagamura P.42	9:50~10:50 Oral Session 18 Stem Cell Source I Masatsugu Tanaka P.43		11:10~12:00 LS9 Precision Medicine for PTCL Speaker: Koji Kato Chair: Shuichi Taniguchi (Meiji Seika Pharma Co., Ltd.)	12:10~13:00 Meet the Expert 1 Speaker: Stephanie J. Lee Moderator: Yoshihiro Inamoto P.11			15:20~16:20 Oral Session 19 Stem Cell Source II Yoshinobu Kanda P.44		17:00~17:50 AS9 Preventing COVID-19 in allogeneic hematopoietic stem cell recipients Speaker: Koji Nagafuji Chair: Tetsuya Nishida (AstraZeneca K.K.)		
	Room 10 (Building 2) 3F 234		8:45~9:45 Oral Session 20 Conditioning I (English Session) Masamitsu Yanada P.45	9:50~10:50 Oral Session 21 Engraftment Failure Tatsuo Ichinohe P.46		11:10~12:00 LS10 Better Hematopoietic cell transplantation medicine Speaker: Yoshiko Atsuta Chair: Emiko Sakaida (Otsuka Pharmaceutical Co., Ltd.)				15:20~16:35 Oral Session 22 Conditioning II Yukiyasu Ozawa P.47		17:00~17:50 AS10 The year after allogeneic HSCT: clinical impact in chronic GVHD control - Current status and future prospects based on clinical cases - Speakers: Yoko Nijima, Makoto Otsuka Chair: Yoshinobu Maeda (Janssen Pharmaceutical K.K.)		
	Room 11 (Building 1) 3F 131 + 132		8:45~9:45 Oral Session 23 Rehabilitation I Yuichiro Nawa P.48	9:50~10:50 Oral Session 24 Rehabilitation II Kazushi Nakamura P.49		11:10~12:00 LS11 Efficacy of hematopoietic stem cell transplantation after allogeneic hematopoietic stem cell transplantation - The evaluation of NK1.1 immunodepletion and GvHD prophylaxis - Speakers: Shingo Fuji, Tomomi Tsukazaki Chair: Masashi Sawwa (CSL Behring K.K.)	12:10~13:00 Meet the Expert 2 Speaker: David Miklos Moderator: Hideki Nakasone P.11		14:40~15:30 Nursing Oral Session 1 HCTC Fertility Emiko Okamoto Aya Miyake P.71	15:40~16:30 Nursing Oral Session 2 Long-term Psychosocial Support Tomomi Mochizuki Nozomi Hamada P.72		17:00~17:50 AS11 Treatment strategy for relapsed/refractory follicular lymphoma Speaker: Noriko Fukuhara Chair: Makoto Murata (Eisai Co., Ltd.)		
	Room 12 (Building 1) 3F 133 + 134		8:45~9:45 Oral Session 25 Viral Infection II Shigeo Fuji P.50	9:50~10:40 Oral Session 26 CD19 CAR-T: Clinical Outcome I Yoshiyuki Takahashi P.51		11:10~12:00 LS12 Conducting the sequential treatment of multiple myeloma - MDQ approach, PFS (S)- Speakers: Hiroyuki Takahashi, Kazuhito Suzuki Chair: Hiroyuki Takamatsu (Sanofi K.K.)	12:10~13:00 Meet the Expert 3 Speaker: Marcelo C. Pasquini Moderator: Junya Kanda P.11			15:20~16:35 Oral Session 27 CD19 CAR-T: Clinical Outcome II Koji Izutsu P.52		17:00~17:50 AS12 Role of subcutaneous treatment of Myeloma and the impact of MDQ approach Speaker: Hang Quach Chair: Kenichi Suzuki (Sanofi K.K.)		
	Room 13 (Building 2) 1F 211					11:10~12:00 LS13 Treatment of aplastic anemia patients with previous indication for allogeneic transplantation Speaker: Ken Ishiyama Chair: Hiroki Yamaguchi (Novartis Pharma K.K.)				15:20~16:35 Oral Session 28 CAR-T: Biomarker Hiroshi Fujiwara P.54		17:00~17:50 AS13 Management of infectious complications in hematopoietic stem cell transplantation patients Speakers: Yasuhiko Ohno, Yuki Inagaki-Mori Chair: Yoshinobu Kanda (Pfizer Japan Inc.)		
Poster (Building 1) 1F Event Hall		8:30~10:00 Poster Mounting	10:00~12:10 Poster Viewing		12:10~13:00 Poster Presentation		13:00~18:00 Poster Viewing							
Exhibition (Building 1) 1F Event Hall		8:30~18:00 Exhibition												